ECM
ALXO icon

ExodusPoint Capital Management’s ALX Oncology ALXO Stock Holding History

ExodusPoint Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,527
Closed -$21K – 1478
2024
Q3 		$21K Buy
+11,527
New +$42.9K ﹤0.01% 1562
2024
Q2 		– Sell
-23,366
Closed -$261K – 1492
2024
Q1 		$261K Sell
23,366
-7,025
-23% -$98.7K ﹤0.01% 1294
2023
Q4 		$453K Buy
+30,391
New +$288K ﹤0.01% 1057
2022
Q3 		– Sell
-187,258
Closed -$1.51M – 1848
2022
Q2 		$1.51M Buy
+187,258
New +$2.04M 0.02% 908

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

ExodusPoint Capital Management's ALXO Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of ALX Oncology (ALXO) in Q4 2024, closing a stake of 11,527 shares — an estimated $21K sold.

ExodusPoint Capital Management first reported a position in ALXO in Q2 2022 and held it in 4 quarters. The position peaked at $1.51M in Q2 2022. 87 funds tracked by Wall St. Rank hold ALXO as of Q4 2024.

  • ExodusPoint Capital Management reported no remaining ALX Oncology position as of Q4 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 11,527 ALX Oncology shares in Q4 2024, an estimated $21K.
  • ExodusPoint Capital Management first reported a position in ALX Oncology in Q2 2022 and held it in 4 quarters.
  • ExodusPoint Capital Management's ALX Oncology position peaked at $1.51M in Q2 2022.
  • 87 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.